LENZ Therapeutics (LENZ) Income from Continuing Operations (2020 - 2026)
LENZ Therapeutics' (LENZ) quarterly Income from Continuing Operations came in at 42207000.0 in Q1 2026, down 165.34% year-on-year from 64599898.87 in Q1 2025, and down 17.58% on a QoQ basis from 35896000.0 in Q4 2025.
LENZ Therapeutics (LENZ) Income from Continuing Operations (2020 - 2026) Analysis & Trends
LENZ Therapeutics (LENZ) has 7 years of Income from Continuing Operations data on file, last reported at 42207000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 165.34% year-over-year to 42207000.0 in Q1 2026; TTM through Mar 2026 was 109715000.0, a 123.78% decrease from a year earlier, with the FY2025 full-year figure at 82127000.0, down 65.02% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 42207000.0, down from 35896000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for LENZ reached as high as 10215000.0 in Q3 2024 and fell as low as 636449000.0 in Q2 2022.
- Historically, Income from Continuing Operations has averaged 61183647.06 across 5 years, with a median of 18178000.0 in 2023.
- Across the five-year window, Income from Continuing Operations slumped 387.6% in 2022 and surged 92.18% in 2023, its largest moves.
- Year by year, Income from Continuing Operations stood at 28346000.0 in 2022, then jumped by 35.87% to 18178000.0 in 2023, then surged by 30.4% to 12652000.0 in 2024, then slumped by 183.72% to 35896000.0 in 2025, then decreased by 17.58% to 42207000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 42207000.0 in Q1 2026, 35896000.0 in Q4 2025, and 16700000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | LENZ Therapeutics | 158.34 Mn | 158.34 Mn | 825,000.00 | -42.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -42.21 Mn |
| Dec 31, 2025 | -35.90 Mn |
| Sep 30, 2025 | -16.70 Mn |
| Jun 30, 2025 | -14.91 Mn |
| Mar 31, 2025 | -15.91 Mn |
| Dec 31, 2024 | -12.65 Mn |
| Sep 30, 2024 | -10.22 Mn |
| Jun 30, 2024 | -10.25 Mn |
| Mar 31, 2024 | -16.14 Mn |
| Dec 31, 2023 | -18.18 Mn |
| Sep 30, 2023 | -53.23 Mn |
| Jun 30, 2023 | -49.79 Mn |
| Mar 31, 2023 | -17.43 Mn |
| Dec 31, 2022 | -28.35 Mn |
| Sep 30, 2022 | -34.23 Mn |
| Jun 30, 2022 | -636.45 Mn |
| Mar 31, 2022 | -27.58 Mn |
| Dec 31, 2021 | -20.94 Mn |
| Sep 30, 2021 | -54.99 Mn |
| Jun 30, 2021 | -130.53 Mn |